Society of Hematologic Oncology

Society of Hematologic Oncology Become a member of SOHO today for free! Register for SBBC at soho.click/SBBC on November 20 SOHO is led by a Board of Directors with six voting members.

SOHO is the only international society for clinicians, scientists & related professionals who specialize in the research & treatment of hematologic malignancies. The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 3,000 members have joined the society from around the globe. In addition, an outstanding group of clinician-scientists have been assembled to serve on the Steering Committee to provide guidance and direction in the continued development of SOHO. Two additional committees, Scientific and Education, are responsible for abstract review and the scientific program of the annual meetings, respectively.

“Clinical Lymphoma, Myeloma & Leukemia,” a peer-reviewed journal published by Elsevier, is the official journal of SOHO. It is available online free-of-charge to SOHO members and at a discounted rate in printed form (click the 'Sign Up' button to become a SOHO member). The SOHO Fifth Annual Meeting is scheduled for September 13-16, 2017 at the Westin Galleria and Oaks in Houston, Texas. The society expects more than 1,000 physicians and related professionals to attend the 3.5-day event. (go to soho2017.com for more information and registration).

Catching Dr. Lonial at the SOHO booth with his Ask-the-Expert counterpart!
12/06/2025

Catching Dr. Lonial at the SOHO booth with his Ask-the-Expert counterpart!

Stay tuned for our lymphoma discussion on CELMods!
12/05/2025

Stay tuned for our lymphoma discussion on CELMods!

Part 3 of coming up at 1:35 pm Central time. Register at soho.click/SBBC.
11/20/2025

Part 3 of coming up at 1:35 pm Central time. Register at soho.click/SBBC.

Safer, more effective ALL therapies still needed, Selina Luger said in this SBBC session on .
11/20/2025

Safer, more effective ALL therapies still needed, Selina Luger said in this SBBC session on .

Despite ALL treatment progress, patients still need safer, more effective options Novel agents have transformed outcomes for patients with relapsed or refractory acute lymphoblastic leukemia (ALL), said Selina Luger, MD, of the University of Pennsylvania, during her SOHO Breakthroughs in Blood Cance...

11/20/2025

Ahead of SBBC—and in the spirit of end-of-year lists—SOHO Insider asked Dr. Vose for her take on the biggest lymphoma developments of 2025. SBBC starts tomorrow. SOHO member register today for free at http://soho.click/SBBC; $50 for non-SOHO members. Join SOHO for free at soho.click/join

Meeting start on November 20, 2025.

FDA approves epcoritamab combo in R/R follicular lymphoma
11/19/2025

FDA approves epcoritamab combo in R/R follicular lymphoma

The US Food and Drug Administration (FDA) has approved epcoritamab (EPKINLY®) in combination with rituximab, lenalidomide (EPKINLY + R2) for adult patients with relapsed or refractory follicular lymphoma (FL). This FDA approval marks the third indication for epcoritamab, according to Genmab, the ma...

Tafasitamab gets positive CHMP opinion in R/R follicular lymphoma
11/18/2025

Tafasitamab gets positive CHMP opinion in R/R follicular lymphoma

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of tafasitamab (Minjuvi)® in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicula...

IDP-023 demonstrates good safety, efficacy in relapsed or refractory myeloma
11/13/2025

IDP-023 demonstrates good safety, efficacy in relapsed or refractory myeloma

In a first-in-human study, IDP-023 demonstrated a promising safety and efficacy profile in patients with relapsed or refractory multiple myeloma, according to findings presented as a late-breaking poster by Krina Patel, MD, of the University of Texas MD Anderson Cancer Center at the 2025 Society for...

FDA approves blenrep combo in relapsed or refractory MM
10/23/2025

FDA approves blenrep combo in relapsed or refractory MM

The US Food and Drug Administration (FDA) has approved belantamab mafodotin (blenrep) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least two prior lines of therapy, including a protea...

ICYMI: VERONA phase 3 trial shows no survival benefit in high-risk MDS
10/21/2025

ICYMI: VERONA phase 3 trial shows no survival benefit in high-risk MDS

The phase 3 VERONA trial did not meet its primary endpoint of overall survival in patients with high-risk myelodysplastic syndromes, according to results presented at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025). The study, presented by Guillermo Garcia-Manero, MD...

10/20/2025

Register today for SOHO's virtual meeting, SOHO Breakthroughs in Blood Cancers (SBBC) at http://soho.click/SBBC. Dr. Sagar Lonial gives a sneak peak at what attendees can expect. SBBC will be held on Nov. 20 & is free 4 SOHO members; $50 for non-SOHO members. Join SOHO for free at soho.click/join.

Address

The Woodlands, TX
77393

Opening Hours

Monday 8am - 6pm
Tuesday 8am - 6pm
Wednesday 8am - 6pm
Thursday 8am - 6pm
Friday 8am - 6pm

Telephone

+12813647387

Website

http://sohoinsider.com/, http://soho.click/SBBC

Alerts

Be the first to know and let us send you an email when Society of Hematologic Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Society of Hematologic Oncology:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

About the Society

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 3,000 members have joined the society from around the globe. SOHO is led by a Board of Directors with eight voting members. In addition, an outstanding group of clinician-scientists have been assembled to serve on the Steering Committee to provide guidance and direction in the continued development of SOHO. Two additional committees, Scientific and Education, are responsible for abstract review and the scientific program of the annual meetings, respectively. “Clinical Lymphoma, Myeloma & Leukemia,” a peer-reviewed journal published by Elsevier, is the official journal of SOHO. It is available online free-of-charge to SOHO members and at a discounted rate in printed form (click the 'Sign Up' button to become a SOHO member). The SOHO Sixth Annual Meeting is scheduled for September 12-15, 2018 at the Hilton Americas-Houston in Houston, Texas. The society expects approximately 1,200 physicians and related professionals to attend the 3.5-day event. (go to soho2018.org for more information, abstract submissions and registration).